CA Patent

CA3256695A1 — Treatments with nirogacestat

Assigned to SpringWorks Therapeutics Inc · Expires 2023-11-23 · 2y expired

What this patent protects

The present disclosure relates to improved methods of treatment with nirogacestat. The present invention further includes improvement methods of treating conditions responsive to inhibition of gamma secretase, such as desmoid tumor, multiple myeloma, ovarian granulosa cell tumors…

USPTO Abstract

The present disclosure relates to improved methods of treatment with nirogacestat. The present invention further includes improvement methods of treating conditions responsive to inhibition of gamma secretase, such as desmoid tumor, multiple myeloma, ovarian granulosa cell tumors, with nirogacestat and pharmaceutically acceptable salts thereof.

Drugs covered by this patent

Patent Metadata

Patent number
CA3256695A1
Jurisdiction
CA
Classification
Expires
2023-11-23
Drug substance claim
No
Drug product claim
No
Assignee
SpringWorks Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.